Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study

Karabük, Emine; Köse, Mehmet; Hızlı, Deniz; Taşkın, Salih; Karadağ, Burak; Turan, Taner; Boran, Nurettin; Özfuttu, Ahmet; Ortaç, Fırat

doi:10.3802/jgo.2013.24.2.160

Cited by 35 publications

(24 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mucinous carcinoma is indolent and has an excellent prognosis when identified at an early stage [ 23 ]. By contrast, advanced-stage mucinous ovarian cancer has a poor prognosis due to its resistance to platinum-based chemotherapy [ 24 ]. In particular, mucinous invasive ovarian cancer is a different disease entity and has distinct characteristics compared to highgrade serous carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Safety of Fertility-Sparing Surgery in Primary Mucinous Carcinoma of the Ovary

Lee

Kim

et al. 2014

Cancer Res Treat

View full text Add to dashboard Cite

PurposeThe aim of this study is to evaluate the safety of fertility-sparing surgery as the treatment for patients with primary mucinous epithelial ovarian cancer.Materials and MethodsA retrospective study of patients with mucinous ovarian cancer between 1991 and 2010 was performed. The demographics and survival outcomes were compared between patients who underwent fertility-sparing surgery and those who underwent radical surgery.ResultsA total of 110 patients underwent primary surgery. At the time of surgery, tumors appeared to be grossly confined to the ovaries in 90 patients, and evidence of metastasis was definite in 20 patients. Of the 90 patients with tumors that appeared to be grossly confined to the ovaries at surgical exploration, 35 (38.9%) underwent fertility-sparing surgery. The Kaplan- Meier curve and the log rank test showed no difference in either recurrence-free survival (p=0.792) or disease-specific survival (p=0.706) between the two groups. Furthermore, there was no significant difference in recurrence-free survival (p=0.126) or disease-specific survival (p=0.377) between the two groups, even when the analysis was limited to women below the age of 40. In a multivariate Cox model, fertility-sparing surgery had no effect on either recurrence-free survival (recurrence hazard ratio [HR], 1.20; 95% confidence interval [CI], 0.25 to 5.71) or disease-specific survival (death HR, 0.88; 95% CI, 0.17 to 4.60).ConclusionFertility-sparing surgery in primary mucinous cancer grossly confined to the ovaries may be a safe option and one not associated with an increase in recurrence or mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety of Fertility-Sparing Surgery in Primary Mucinous Carcinoma of the Ovary

Lee

Kim

et al. 2014

Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…By contrast, mucinous and clear cell cancers are primarily resistant to chemotherapies (23). Patients with advanced-stage mucinous ovarian cancer exhibit higher rates of chemoresistance and have poorer survival outcomes compared with those with advanced-stage high-grade serous ovarian cancer (33).…”

Section: Molecular Mechanism Of Wnt Signaling Implicated In Chemoresimentioning

confidence: 99%

Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer (Review)

et al. 2018

View full text Add to dashboard Cite

Abstract. Cases of mucinous ovarian cancer are predominantly resistant to chemotherapies. The present review summarizes current knowledge of the therapeutic potential of targeting the Wingless (WNT) pathway, with particular emphasis on preclinical and clinical studies, for improving the chemoresistance and treatment of mucinous ovarian cancer. A review was conducted of English language literature published between January 2000 and October 2017 that concerned potential signaling pathways associated with the chemoresistance of mucinous ovarian cancer. The literature indicated that aberrant activation of growth factor and WNT signaling pathways is specifically observed in mucinous ovarian cancer. An evolutionarily conserved signaling cascade system including epidermal growth factor/RAS/RAF/mitogen-activated protein kinase kinase/extracellular signal-regulated protein kinase, phosphoinositide 3-kinase/Akt and WNT signaling regulates a variety of cellular functions; their crosstalk mutually enhances signaling activity and induces chemoresistance. Novel antagonists, modulators and inhibitors have been developed for targeting the components of the WNT signaling pathway, namely Frizzled, low-density lipoprotein receptor-related protein 5/6, Dishevelled, casein kinase 1, AXIN, glycogen synthase kinase 3β and β-catenin. Targeted inhibition of WNT signaling represents a rational and promising novel approach to overcome chemoresistance, and several WNT inhibitors are being evaluated in preclinical studies. In conclusion, the WNT receptors and their downstream components may serve as novel therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer.

show abstract

“…In answering our review question, four studies were judged as having a ‘moderate’ overall risk of bias and 12 studies were considered at ‘serious’ risk of bias . Five studies had one or more domain with a ‘critical’ risk of bias, automatically leading to an overall study judgement of ‘critical’ and exclusion from this review (see Figure S1) .…”

Section: Resultsmentioning

confidence: 99%